Hugel, Inc. (145020.KQ) Stock

145020.KQ logo

Hugel, Inc.

145020.KQSouth Korea
Healthcare

Company profile

Hugel reported revenue of 373.05 billion KRW for fiscal year 2024, up 16.7% from fiscal year 2023, and net income of 135.81 billion KRW. That is a net profit margin of 36.4% for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was 105.90 billion KRW, up 0.8% from a year before. Korea was its largest region in fiscal year 2025, with 35% of revenue. In Q3 2025 it reported net income of 36.81 billion KRW, against net income of 40.26 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 281.68 billion KRW in fiscal year 2022 to 373.05 billion KRW in fiscal year 2024, 15.1% a year on average.

What stands out

  • Its net profit margin over the last four reported quarters was 26.4%, against a median of -8.9% for 6 listed companies of similar size in its industry.
  • Revenue and net income in fiscal year 2024 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2024.

About Hugel, Inc.

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.

Largest shareholders

  • Aphrodite Acquisition Holdings LLC44.48%
  • Hugel, Inc.11.99%
  • Massachusetts Financial Services Co.4.96%
  • Carmignac UK Ltd.0.68%
  • AEGON Investment Management BV0.52%

Share of the company, as of September 25, 2026

Leadership

  • Daniel Chang — Chief Executive Officer
  • Carrie C. Strom — President & Global CEO, 47
  • J. T. Kim — MD & CFO
  • Soon-Woo Kwon — VP & Chief Production Officer, 55
  • Jennifer Rho — MD & Chief Strategy Officer

How much revenue does Hugel make?

Hugel reported 373.05 billion KRW in revenue for fiscal year 2024, up 16.7% from 319.70 billion KRW in fiscal year 2023. In Q3 2025 revenue was 105.90 billion KRW.

Where does Hugel make most of its revenue?

Korea: 35% of revenue by region in fiscal year 2025, followed by Asia (30%).

What companies are similar to Hugel?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hanmi Pharm. Co., Ltd. (128940.KS), Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ), Celltrion Pharm, Inc. (068760.KQ).

How does Hugel's profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Hugel, 26.4%; Hanmi Pharm. Co., Ltd. (128940.KS), 0.0%; Hanall Biopharma Co., Ltd. (009420.KS), -15.3%; LigaChem Biosciences Inc. (141080.KQ), -180.9%; Celltrion Pharm, Inc. (068760.KQ), 9.5%; OliX Pharmaceuticals, Inc (226950.KQ), -102.9%; GC Biopharma Corp. (006280.KS), -2.5%.

How has Hugel's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 211.04 billion KRW; FY2021, 231.86 billion KRW; FY2022, 281.68 billion KRW; FY2023, 319.70 billion KRW; FY2024, 373.05 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
FoundedNov 22, 2001
IPO DateDec 24, 2015
IPO StatusPublic
HeadquartersChuncheon-si, South Korea
FoundersSung Bum-Hong
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
61-20, Sinbuk-ro, Chuncheon-si, 24206
Phone
82 3 3255 3882
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Hugel, Inc. (145020.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/145020.KQ

LinkedInLinkedInXXYouTubeYouTube